Clinical Trial Without IND for a Supplement Gets Warning Letter 

The FDA just called out another non-IND clinical trial with a supplement claiming medical benefits. An FDA inspection revealed that the sponsor of a Relaxium® Sleep study bypassed critical regulatory steps, raising serious concerns about participant safety and data integrity in unapproved clinical trials. In a Warning Letter to the American Behavioral Research Institute (ABRI), … Read more

FDA’s CNPV Program Aims to Revolutionize Drug Reviews — But Will It Deliver?

The FDA has officially launched a new review voucher, the Commissioner’s National Priority Voucher (CNPV), an initiative to accelerate the review timeline for new drugs and biologics. The program promises to shorten FDA review time from the current 6–12 months (under PDUFA timelines) to as little as 1–2 months. Targeting products that align with U.S. … Read more